Diet-induced obesity predisposes anti-PD-1 antibody-treated mice to imiquimod-mediated psoriasiform dermatitis: implications for immune-related adverse events in cancer patients treated with anti-PD-1

被引：0
|
作者：
Yu, S. [1 ,2 ]
Wu, X. [2 ]
Shi, Z. [2 ]
Huynh, M. [2 ]
Hwang, S. T. [2 ]
机构：
[1] Kaohsiung Med Univ, Dept Dermatol, Kaohsiung, Taiwan
[2] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2019年 / 139卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
022
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [41] Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
    Joseph, Richard W.
    Cappel, Mark
    Goedjen, Brent
    Gordon, Matthew
    Kirsch, Brandon
    Gilstrap, Cheryl
    Bagaria, Sanjay
    Jambusaria-Pahlajani, Anokhi
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (01) : 18 - 22
  • [42] Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies
    Zhang, Qing
    Wang, Zhe
    Zeng, Xueqin
    Ding, Yi
    Wang, Chen
    BMC CANCER, 2025, 25 (01)
  • [43] Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
    Matsuoka, Hiroshi
    Hayashi, Takahiro
    Takigami, Karen
    Imaizumi, Kazuyoshi
    Shiroki, Ryoichi
    Ohmiya, Naoki
    Sugiura, Kazumitsu
    Kawada, Kenji
    Sawaki, Akira
    Maeda, Koutaro
    Ando, Yousuke
    Uyama, Ichiro
    BMC CANCER, 2020, 20 (01)
  • [44] Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
    Hiroshi Matsuoka
    Takahiro Hayashi
    Karen Takigami
    Kazuyoshi Imaizumi
    Ryoichi Shiroki
    Naoki Ohmiya
    Kazumitsu Sugiura
    Kenji Kawada
    Akira Sawaki
    Koutaro Maeda
    Yousuke Ando
    Ichiro Uyama
    BMC Cancer, 20
  • [45] Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy
    Narvaez, J.
    Juarez-Lopez, P.
    LLuch, J.
    Narvaez, J. A.
    Palmero, R.
    Garcia del Muro, X.
    Nolla, J. M.
    Domingo-Domenech, E.
    AUTOIMMUNITY REVIEWS, 2018, 17 (10) : 1040 - 1045
  • [46] The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events
    Fujisaki, Toshiya
    Watanabe, Satoshi
    Ota, Takeshi
    Kushiro, Kohei
    Sato, Yusuke
    Takahashi, Miho
    Ohtsubo, Aya
    Shoji, Satoshi
    Nozaki, Koichiro
    Ichikawa, Kosuke
    Hokari, Satoshi
    Kondo, Rie
    Miyabayashi, Takao
    Abe, Tetsuya
    Miura, Satoru
    Tanaka, Hiroshi
    Okajima, Masaaki
    Terada, Masaki
    Matsumoto, Naoya
    Ishida, Takashi
    Iwashima, Akira
    Sato, Kazuhiro
    Yoshizawa, Hirohisa
    Aoki, Nobumasa
    Hayashi, Masachika
    Ohshima, Yasuyoshi
    Koya, Toshiyuki
    Kikuchi, Toshiaki
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy
    Shafqat, Hammad
    Gourdin, Theodore
    Sion, Amy
    SEMINARS IN ONCOLOGY, 2018, 45 (03) : 156 - 163
  • [48] Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review
    Konstantina, Thomopoulou
    Konstantinos, Rounis
    Anastasios, Koutsopoulos
    Anastasi, Mala
    Eleni, Lagoudaki
    Ioannis, Sougklakos
    Sofia, Agelaki
    Dimitris, Mavroudis
    LUNG CANCER, 2019, 135 : 29 - 32
  • [49] Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1
    Kfoury, M.
    Voisin, A-L.
    Najean, M.
    Champiat, S.
    Laghouati, S.
    Michot, J-M.
    Robert, C.
    Mateus, C.
    Albiges, L.
    Besse, B.
    Massard, C.
    Texier, M.
    Lambotte, O.
    Marabelle, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody
    Fujita, Kohei
    Yamamoto, Yuki
    Kanai, Osamu
    Okamura, Misato
    Hashimoto, Masayuki
    Nakatani, Koichi
    Sawai, Satoru
    Mio, Tadashi
    THORACIC CANCER, 2020, 11 (01) : 15 - 18
12345